Confirm Essential Document Coverage
Evaluate whether required documents are present, applicable, finalized and available across the expected trial milestones and functional areas.
Independent, risk-based Trial Master File audits for sponsors, CROs, biotechnology companies and research organizations seeking stronger document quality, inspection readiness, sponsor oversight and reliable reconstruction of clinical trial conduct.
TMF audits assess whether essential records are created, reviewed, filed, maintained and retained through a controlled process that supports inspection readiness and reliable trial reconstruction.
Evaluate whether required documents are present, applicable, finalized and available across the expected trial milestones and functional areas.
Review document quality, metadata, signatures, version control, filing timeliness and consistency between the TMF and operational activity.
Assess whether sponsor, CRO, vendor and study-team responsibilities are clearly defined, monitored, escalated and supported by evidence.
TMF risk often develops where filing is delayed, document ownership is unclear, oversight is fragmented or quality review focuses on volume instead of the reliability of the inspection narrative.
Required records are absent, incomplete or filed too late to demonstrate contemporaneous trial oversight and execution.
Documents are misclassified, duplicated, incorrectly dated or filed under inconsistent naming and indexing conventions.
Delegated TMF responsibilities are not supported by clear metrics, governance, escalation and documented sponsor review.
Teams cannot retrieve evidence quickly, explain document gaps or demonstrate how TMF quality and completeness are actively controlled.
Audit scope can focus on one trial, one region, a functional area, a CRO, a vendor, the overall eTMF system or a broader portfolio-level inspection-readiness program.
Independent review of a specific trial’s essential documents, milestones, quality indicators and inspection-readiness status.
Evaluation of the systems, procedures, roles, metrics and governance used to manage TMF quality across multiple studies.
Assessment of electronic TMF governance, user access, audit trails, configuration, workflow control and record integrity.
Independent assessment of outsourced TMF activities, responsibilities, quality controls and sponsor oversight.
Focused review designed to identify critical document, retrieval, governance and explanation risks before regulatory inspection.
Focused independent review where significant document, oversight, system or data-integrity concerns require urgent assessment.
The final scope is adapted to study phase, trial complexity, outsourcing model, eTMF environment, previous findings and inspection exposure.
The process is designed to provide objective evidence, clear risk classification and practical recommendations for clinical, QA, TMF operations and leadership teams.
Understand the study, phase, regions, systems, vendors, previous findings and business purpose of the audit.
Define review criteria, sampling approach, zones, milestones, functions and high-risk areas requiring deeper assessment.
Review TMF plans, indexes, completeness reports, metrics, procedures, oversight records and known quality issues.
Evaluate essential documents, metadata, filing timeliness, quality, traceability and consistency across selected samples.
Assess roles, workflows, eTMF controls, vendor oversight, escalation and management visibility.
Deliver risk-ranked findings, remediation priorities and optional CAPA review or effectiveness verification.
Deliverables can be adapted to routine assurance, inspection preparation, vendor oversight, remediation or for-cause review.
TMF audits can support routine quality assurance, study closeout, inspection preparation, vendor oversight or urgent remediation.
The study TMF requires rapid assessment before inspector access or document requests begin.
The organization needs confidence that the TMF is complete, final and suitable for archival.
Delayed filing has created uncertainty regarding completeness, timeliness and inspection exposure.
Outsourced TMF activities require independent review of quality, governance and sponsor oversight.
Records are moving between systems and require assurance over completeness, metadata and traceability.
Repeat document or filing errors indicate a possible systemic process weakness.
Leadership needs an independent view of TMF quality across multiple studies, programs or vendors.
Serious document, data or oversight concerns require confidential and focused independent assurance.
Independent TMF audits help organizations identify documentation risk earlier, strengthen sponsor oversight and improve confidence that trial conduct can be reconstructed from reliable evidence.
Identify critical document, retrieval and explanation gaps before regulatory scrutiny.
Improve visibility over CRO, vendor and study-team TMF performance, escalation and accountability.
Improve confidence that the TMF provides a complete, timely and credible reconstruction of clinical trial conduct.
Common questions from sponsors, CROs, biotechnology companies and research organizations considering independent TMF audit support.
Yes. When secure system access and documentation are available, TMF audits can usually be conducted remotely, onsite or through a hybrid model.
Yes. The scope can focus on one trial, selected countries, sites, functional areas, milestones or high-risk document zones.
Yes. The audit can include system governance, validation, access, workflows, metadata, audit trails, retention and document-integrity controls.
Yes. The audit can evaluate delegated responsibilities, quality agreements, completeness, timeliness, governance and documented sponsor oversight.
Yes. Support can include root cause review, backlog prioritization, CAPA adequacy assessment, remediation planning and follow-up effectiveness verification.
Yes. TMF audit engagements are handled confidentially, and NDA-based collaboration can be used where required.